$599
Lilly Raises FY Guidance by $3B; Lilly Q2 ’24 Earnings; Novo Q2 ’24 London Event
Two cardiometabolic-related news items have been observed: Lilly hosted its Q2 ’24 earnings call (press release; slides) and raised its FY2024 revenue guidance by $3.0B; and Novo Nordisk hosted its post-Q2 ’24 earnings London analyst event (view webcast). Below, FENIX provides highlights and insights for the respective calls.